| 1 |
30033593 | Inhibition of Cyclin-Dependent Kinase 5: A Strategy to Improve Sorafenib Response in Hepatocellular Carcinoma Therapy. | 2019 Jan |
2 |
| 2 |
31439587 | PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. | 2019 Nov 15 |
1 |
| 3 |
31496920 | CDK5 neutralizes the tumor suppressing effect of BIN1 via mediating phosphorylation of c-MYC at Ser-62 site in NSCLC. | 2019 |
1 |
| 4 |
27991934 | Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. | 2017 Jun 8 |
1 |
| 5 |
25395429 | Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma. | 2015 Jan 15 |
1 |
| 6 |
25962959 | Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. | 2015 Jun 20 |
1 |
| 7 |
25217392 | Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients. | 2014 Nov |
1 |
| 8 |
23053255 | Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies. | 2012 Dec |
1 |